| Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing L Rasche, SS Chavan, OW Stephens, PH Patel, R Tytarenko, C Ashby, ... Nature communications 8 (1), 268, 2017 | 350 | 2017 |
| Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL J Duell, M Dittrich, T Bedke, T Mueller, F Eisele, A Rosenwald, L Rasche, ... Leukemia 31 (10), 2181-2190, 2017 | 230 | 2017 |
| Low expression of hexokinase-2 is associated with false-negative FDG–positron emission tomography in multiple myeloma L Rasche, E Angtuaco, JE McDonald, A Buros, C Stein, C Pawlyn, ... Blood, The Journal of the American Society of Hematology 130 (1), 30-34, 2017 | 216 | 2017 |
| Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma N Weinhold, C Ashby, L Rasche, SS Chavan, C Stein, OW Stephens, ... Blood, The Journal of the American Society of Hematology 128 (13), 1735-1744, 2016 | 216 | 2016 |
| Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma MC Da Vià, O Dietrich, M Truger, P Arampatzi, J Duell, A Heidemeier, ... Nature medicine 27 (4), 616-619, 2021 | 173 | 2021 |
| EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT L Rasche, M Kapp, H Einsele, S Mielke Bone marrow transplantation 49 (2), 163-167, 2014 | 140 | 2014 |
| Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma L Rasche, D Alapat, M Kumar, G Gershner, J McDonald, CP Wardell, ... Leukemia 33 (7), 1713-1722, 2019 | 135 | 2019 |
| Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma A Besse, SC Stolze, L Rasche, N Weinhold, GJ Morgan, M Kraus, J Bader, ... Leukemia 32 (2), 391-401, 2018 | 118 | 2018 |
| Central nervous system involvement by multiple myeloma: a multi‐institutional retrospective study of 172 patients in daily clinical practice A Jurczyszyn, N Grzasko, A Gozzetti, J Czepiel, A Cerase, V Hungria, ... American journal of hematology 91 (6), 575-580, 2016 | 115 | 2016 |
| Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases L Rasche, C Bernard, MS Topp, M Kapp, J Duell, C Wesemeier, ... Annals of hematology 91, 1031-1037, 2012 | 114 | 2012 |
| Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M3P) KM Kortüm, C Langer, J Monge, L Bruins, YX Zhu, CX Shi, P Jedlowski, ... Annals of hematology 94, 1205-1211, 2015 | 107 | 2015 |
| GRP78-directed immunotherapy in relapsed or refractory multiple myeloma-results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6 L Rasche, J Duell, IC Castro, V Dubljevic, M Chatterjee, S Knop, F Hensel, ... Haematologica 100 (3), 377, 2015 | 96 | 2015 |
| The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma L Rasche, EJ Angtuaco, TL Alpe, GH Gershner, JE McDonald, RS Samant, ... Blood, The Journal of the American Society of Hematology 132 (1), 59-66, 2018 | 92 | 2018 |
| Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations L Rosiñol, M Beksac, E Zamagni, NWCJ Van de Donk, KC Anderson, ... British journal of haematology 194 (3), 496-507, 2021 | 84 | 2021 |
| Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated … JR Jones, N Weinhold, C Ashby, BA Walker, C Wardell, C Pawlyn, ... Haematologica 104 (7), 1440, 2019 | 83 | 2019 |
| ‘Real‐life’experience of preapproval carfilzomib‐based therapy in myeloma–analysis of cardiac toxicity and predisposing factors S Danhof, M Schreder, L Rasche, S Strifler, H Einsele, S Knop European journal of haematology 97 (1), 25-32, 2016 | 81 | 2016 |
| The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma S Thanendrarajan, E Tian, P Qu, P Mathur, C Schinke, F van Rhee, ... Haematologica 102 (9), e364, 2017 | 80 | 2017 |
| Extramedullary disease in multiple myeloma: a systematic literature review J Bladé, M Beksac, J Caers, A Jurczyszyn, M von Lilienfeld-Toal, ... Blood Cancer Journal 12 (3), 45, 2022 | 79 | 2022 |
| The natural human IgM antibody PAT-SM6 induces apoptosis in primary human multiple myeloma cells by targeting heat shock protein GRP78 L Rasche, J Duell, C Morgner, M Chatterjee, F Hensel, A Rosenwald, ... PloS one 8 (5), e63414, 2013 | 76 | 2013 |
| Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker SS Chavan, J He, R Tytarenko, S Deshpande, P Patel, M Bailey, CK Stein, ... Blood cancer journal 7 (2), e535-e535, 2017 | 71 | 2017 |
